Csenge Advisory Group Has $1.74 Million Stake in SPDR S&P Biotech ETF (XBI)

Share on StockTwits

Csenge Advisory Group reduced its stake in shares of SPDR S&P Biotech ETF (NYSEARCA:XBI) by 1.3% during the 1st quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 19,247 shares of the exchange traded fund’s stock after selling 257 shares during the quarter. Csenge Advisory Group’s holdings in SPDR S&P Biotech ETF were worth $1,742,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in XBI. JPMorgan Chase & Co. lifted its position in shares of SPDR S&P Biotech ETF by 98.7% during the 3rd quarter. JPMorgan Chase & Co. now owns 3,265,715 shares of the exchange traded fund’s stock worth $313,084,000 after buying an additional 1,622,372 shares during the last quarter. Deutsche Bank AG bought a new stake in shares of SPDR S&P Biotech ETF during the 4th quarter worth $139,893,000. Q3 Asset Management bought a new stake in shares of SPDR S&P Biotech ETF during the 1st quarter worth $3,285,000. Duality Advisers LP bought a new stake in shares of SPDR S&P Biotech ETF during the 4th quarter worth $51,363,000. Finally, Main Management ETF Advisors LLC lifted its position in shares of SPDR S&P Biotech ETF by 6.1% during the 4th quarter. Main Management ETF Advisors LLC now owns 266,400 shares of the exchange traded fund’s stock worth $19,114,000 after buying an additional 15,300 shares during the last quarter.

Shares of XBI stock opened at $82.56 on Friday. SPDR S&P Biotech ETF has a twelve month low of $64.38 and a twelve month high of $101.55.

ILLEGAL ACTIVITY NOTICE: “Csenge Advisory Group Has $1.74 Million Stake in SPDR S&P Biotech ETF (XBI)” was first reported by Fairfield Current and is owned by of Fairfield Current. If you are reading this story on another domain, it was copied illegally and reposted in violation of US & international copyright & trademark law. The correct version of this story can be read at https://www.fairfieldcurrent.com/news/2019/05/19/csenge-advisory-group-has-1-74-million-stake-in-spdr-sp-biotech-etf-xbi.html.

About SPDR S&P Biotech ETF

SPDR S&P Biotech ETF (the Fund) seeks to closely match the returns and characteristics of the S&P Biotechnology Select Industry Index. The S&P Biotechnology Select Industry Index represents the biotechnology sub-industry portion of the S&P Total Markets Index. The S&P TMI tracks all the United States common stocks listed on the New York Stock Exchange, American Stock Exchange, National Association of Securities Dealers Automated Quotation (NASDAQ) National Market and NASDAQ Small Cap exchanges.

Featured Story: Purposes and Functions of the Federal Reserve

Want to see what other hedge funds are holding XBI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for SPDR S&P Biotech ETF (NYSEARCA:XBI).

Institutional Ownership by Quarter for SPDR S&P Biotech ETF (NYSEARCA:XBI)

Receive News & Ratings for SPDR S&P Biotech ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SPDR S&P Biotech ETF and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply